Trial Outcomes & Findings for A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (NCT NCT01074008)

NCT ID: NCT01074008

Last Updated: 2015-01-08

Results Overview

Plasma HCV RNA levels (reported as log10 IU/mL) were determined for each sample using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay that had a lower limit of detection of 10 IU/mL and a lower limit of quantification of 25 IU/mL. The baseline value was the HCV RNA level before the first dose of study drug on Day 1. The maximal change during monotherapy was the difference from baseline to the lowest log10 HCV RNA level anytime after the first dose of study drug on Day 1 through the last log10 HCV RNA level before the first dose of study drug on Day 4. Data are reported as the mean ± standard deviation.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 74 participants
• Primary outcome timeframe: Prior to dosing on Day 1 to before the morning dose on Day 4
• Results posted on: 2015-01-08

Participant Flow

Participant milestones

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Overall Study STARTED	8	8	8	8	8	7	8	8	11
Overall Study Completed Direct-acting Antiviral Agent	8	7	7	8	8	5	8	7	5
Overall Study COMPLETED	7	5	6	7	6	7	7	8	7
Overall Study NOT COMPLETED	1	3	2	1	2	0	1	0	4

Reasons for withdrawal

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Overall Study Adverse Event	0	1	0	0	0	0	0	0	0
Overall Study Withdrawal by Subject	1	1	1	0	1	0	0	0	0
Overall Study Lost to Follow-up	0	1	1	1	1	0	1	0	4

Baseline Characteristics

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Baseline characteristics by cohort

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV n=8 Participants Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV n=8 Participants Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV n=11 Participants Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Total n=74 Participants Total of all reporting groups
Age, Continuous	48.4 years STANDARD_DEVIATION 9.36 • n=5 Participants	50.9 years STANDARD_DEVIATION 2.59 • n=7 Participants	50.6 years STANDARD_DEVIATION 9.26 • n=5 Participants	53.5 years STANDARD_DEVIATION 5.40 • n=4 Participants	51.3 years STANDARD_DEVIATION 7.76 • n=21 Participants	40.9 years STANDARD_DEVIATION 11.25 • n=10 Participants	49.6 years STANDARD_DEVIATION 8.37 • n=115 Participants	53.5 years STANDARD_DEVIATION 6.46 • n=6 Participants	51.5 years STANDARD_DEVIATION 6.36 • n=6 Participants	50.2 years STANDARD_DEVIATION 8.01 • n=64 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	2 Participants n=115 Participants	0 Participants n=6 Participants	2 Participants n=6 Participants	16 Participants n=64 Participants
Sex: Female, Male Male	7 Participants n=5 Participants	5 Participants n=7 Participants	4 Participants n=5 Participants	5 Participants n=4 Participants	7 Participants n=21 Participants	7 Participants n=10 Participants	6 Participants n=115 Participants	8 Participants n=6 Participants	9 Participants n=6 Participants	58 Participants n=64 Participants

PRIMARY outcome

Timeframe: Prior to dosing on Day 1 to before the morning dose on Day 4

Population: Participants received at least one dose of study drug (direct-acting antiviral agent) and have both baseline and at least one post-baseline measurement of HCV RNA levels during monotherapy treatment.

Plasma HCV RNA levels (reported as log10 IU/mL) were determined for each sample using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay that had a lower limit of detection of 10 IU/mL and a lower limit of quantification of 25 IU/mL. The baseline value was the HCV RNA level before the first dose of study drug on Day 1. The maximal change during monotherapy was the difference from baseline to the lowest log10 HCV RNA level anytime after the first dose of study drug on Day 1 through the last log10 HCV RNA level before the first dose of study drug on Day 4. Data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV n=8 Participants Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV n=8 Participants Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV n=11 Participants Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-450/r, ABT-333, or ABT-072 Monotherapy Treatment	-4.07 log10 IU/mL Standard Deviation 0.53	-3.91 log10 IU/mL Standard Deviation 0.42	-4.11 log10 IU/mL Standard Deviation 0.32	-1.14 log10 IU/mL Standard Deviation 0.99	-1.07 log10 IU/mL Standard Deviation 0.41	-1.57 log10 IU/mL Standard Deviation 0.94	-1.08 log10 IU/mL Standard Deviation 0.68	-0.95 log10 IU/mL Standard Deviation 0.68	-0.36 log10 IU/mL Standard Deviation 0.13

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ABT-450 using validated analytical methods. The maximum plasma concentration (Cmax; measured in ng/mL) is the highest concentration that a drug achieves in the blood after administration in a dosing interval. The Cmax of ABT-450 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Maximum Plasma Concentration (Cmax) of ABT-450	34.4 ng/mL Standard Deviation 31.7	165 ng/mL Standard Deviation 221	2923 ng/mL Standard Deviation 2026	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ABT-450 using validated analytical methods. The time to maximum plasma concentration (Tmax; measured in hours) is the time it takes for a drug to achieve Cmax. The Tmax of ABT-450 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Time to Maximum Plasma Concentration (Tmax) of ABT-450	2.5 Hours Standard Deviation 0.9	4.8 Hours Standard Deviation 3.5	3.0 Hours Standard Deviation 1.1	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ABT-450 using validated analytical methods. The area under the plasma concentration-time curve (AUC; measured in ng*hr/mL) is a method of measurement to determine the total exposure of a drug in blood plasma. The AUC24 of ABT-450 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450	250 ng*hr/mL Standard Deviation 245	1122 ng*hr/mL Standard Deviation 992	17351 ng*hr/mL Standard Deviation 15841	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ritonavir using validated analytical methods. The maximum plasma concentration (Cmax; measured in ng/mL) is the highest concentration that a drug achieves in the blood after administration in a dosing interval. The Cmax of ritonavir was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Maximum Plasma Concentration (Cmax) of Ritonavir	563 ng/mL Standard Deviation 674	851 ng/mL Standard Deviation 638	1098 ng/mL Standard Deviation 619	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ritonavir using validated analytical methods. The time to maximum plasma concentration (Tmax; measured in hours) is the time it takes for a drug to achieve Cmax. The Tmax of ritonavir was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Time to Maximum Plasma Concentration (Tmax) of Ritonavir	4.8 Hours Standard Deviation 2.8	5.3 Hours Standard Deviation 3.2	4.5 Hours Standard Deviation 1.4	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ritonavir using validated analytical methods. The area under the plasma concentration-time curve (AUC; measured in ng*hr/mL) is a method of measurement to determine the total exposure of a drug in blood plasma. The AUC24 of ritonavir was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir	4518 ng*hr/mL Standard Deviation 5063	7638 ng*hr/mL Standard Deviation 6284	8663 ng*hr/mL Standard Deviation 5006	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ABT-072 using validated analytical methods. The maximum plasma concentration (Cmax; measured in ng/mL) is the highest concentration that a drug achieves in the blood after administration in a dosing interval. The Cmax of ABT-072 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Maximum Plasma Concentration (Cmax) of ABT-072	390 ng/mL Standard Deviation 153	1218 ng/mL Standard Deviation 382	1748 ng/mL Standard Deviation 707	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ABT-072 using validated analytical methods. The time to maximum plasma concentration (Tmax; measured in hours) is the time it takes for a drug to achieve Cmax. The Tmax of ABT-072 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Time to Maximum Plasma Concentration (Tmax) of ABT-072	4.5 Hours Standard Deviation 1.4	2.8 Hours Standard Deviation 1.0	3.1 Hours Standard Deviation 1.1	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ABT-072 using validated analytical methods. The area under the plasma concentration-time curve (AUC; measured in ng*hr/mL) is a method of measurement to determine the total exposure of a drug in blood plasma. The AUC24 of ABT-072 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-072	3678 ng*hr/mL Standard Deviation 1742	9413 ng*hr/mL Standard Deviation 3125	14126 ng*hr/mL Standard Deviation 6102	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ABT-333 using validated analytical methods. The maximum plasma concentration (Cmax; measured in ng/mL) is the highest concentration that a drug achieves in the blood after administration in a dosing interval. The Cmax of ABT-333 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=6 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Maximum Plasma Concentration (Cmax) of ABT-333	800 ng/mL Standard Deviation 382	1201 ng/mL Standard Deviation 419	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose)

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours); 2, 4, 8, 12, and 16 hours after the morning dose on Day 1; and prior to dose on Day 2 (24 hours after Day 1 dose). The samples were analyzed for the concentration of ABT-333 using validated analytical methods. The time to maximum plasma concentration (Tmax; measured in hours) is the time it takes for a drug to achieve Cmax. The Tmax of ABT-333 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=6 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Time to Maximum Plasma Concentration (Tmax) of ABT-333	4.5 Hours Standard Deviation 5.2	7.0 Hours Standard Deviation 8.4	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Immediately prior to morning dose (time 0 hours) and at 2, 4, 8, and 12 hours after the morning dose on Day 1

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the pharmacokinetic analysis.

Blood samples were collected immediately prior to morning dose (time 0 hours) and at 2, 4, 8, and 12 hours after the morning dose on Day 1. The samples were analyzed for the concentration of ABT-333 using validated analytical methods. The area under the plasma concentration-time curve (AUC; measured in ng*hr/mL) is a method of measurement to determine the total exposure of a drug in blood plasma. The AUC12 of ABT-333 was estimated using non-compartmental methods and data are reported as the mean ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=6 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333	4315 ng*hr/mL Standard Deviation 2176	6431 ng*hr/mL Standard Deviation 1914	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Week 4

Population: All participants who received at least one dose of study drug and had at least one post-baseline HCV RNA value were included in this efficacy analysis.

Plasma hepatitis C virus ribonucleic acid (HCV RNA) levels were determined for each sample using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay that had a lower limit of detection of 10 IU/mL and a lower limit of quantification (LLOQ) of 25 IU/mL. Rapid virologic response was defined as HCV RNA level < LLOQ (< 25 IU/mL) at Week 4. Data are reported as the percentage of participants with RVR.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV n=8 Participants Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV n=8 Participants Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV n=11 Participants Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Percentage of Participants With Rapid Virologic Response (RVR) at Week 4	87.5 percentage of participants	75.0 percentage of participants	100.0 percentage of participants	37.5 percentage of participants	12.5 percentage of participants	42.9 percentage of participants	50.0 percentage of participants	50.0 percentage of participants	9.1 percentage of participants

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: To be included in the efficacy analysis, participants received at least one dose of study drug (direct-acting antiviral agent) and at least one post-baseline measurement of HCV RNA levels.

Plasma hepatitis C virus ribonucleic acid (HCV RNA) levels were determined for each sample using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay that had a lower limit of detection of 10 IU/mL and a lower limit of quantification of 25 IU/mL. Partial early virologic response (EVR) was defined as HCV RNA levels that decreased > 2 log10 IU/mL at Week 12 as compared to baseline. The baseline value was the last measurement before the first dose on Day 1. Data are reported as the percentage of participants with partial EVR.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV n=8 Participants Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV n=8 Participants Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV n=11 Participants Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Percentage of Participants With Partial Early Virologic Response (EVR) at Week 12	100.0 percentage of participants	87.5 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	62.5 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	36.4 percentage of participants

SECONDARY outcome

Timeframe: Week 12

Population: To be included in the efficacy analysis, participants received at least one dose of study drug (direct-acting antiviral agent) and have at least one post-baseline measurement of HCV RNA levels.

Plasma hepatitis C virus ribonucleic acid (HCV RNA) levels were determined for each sample using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay that had a lower limit of detection of 10 IU/mL and a lower limit of quantification (LLOQ) of 25 IU/mL. Complete EVR was defined as HCV RNA levels < LLOQ (< 25 IU/mL) at Week 12. Data are reported as the percentage of participants with cEVR.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV n=8 Participants Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV n=8 Participants Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV n=11 Participants Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Percentage of Participants With Complete Early Virologic Response (cEVR) at Week 12	87.5 percentage of participants	87.5 percentage of participants	100.0 percentage of participants	75.0 percentage of participants	50.0 percentage of participants	85.7 percentage of participants	87.5 percentage of participants	62.5 percentage of participants	18.2 percentage of participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and Day 4

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the analysis. When the number of participants used to analyze the data at a specific time point differs from the Number of Participants Analyzed, the n (number of participants) is denoted in the Category Title.

Baseline samples were analyzed for resistance-associated amino acid variants using population and clonal sequencing and were compared with the appropriate reference sequence (1a-H77 or 1b-Con1). Phenotypic resistance to ABT-450 at baseline was assessed by calculating the fold difference in the half maximal effective concentration (EC50) compared with the EC50 for the appropriate reference replicon (1a-H77 or 1b-Con1). Available samples at Day 4 with HCV RNA ≥ 1000 IU/mL were analyzed for resistance-associated variants using population and clonal sequencing and were compared with the baseline sequences to assess amino acid changes. Phenotypic resistance to ABT-450 at Day 4 was assessed by calculating the fold difference in the EC50 compared with the EC50 for the corresponding baseline sample. The number of participants with variants at resistance-associated amino acid positions and phenotypic resistance are presented.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-450 in Non-structural Viral Protein 3 (NS3) Baseline Variants in NS3	0 participants	0 participants	0 participants	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-450 in Non-structural Viral Protein 3 (NS3) Baseline Resistance to ABT-450 >10-fold	0 participants	0 participants	0 participants	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-450 in Non-structural Viral Protein 3 (NS3) Day 4 Variants in NS3 (n=3, 2, 3)	2 participants	2 participants	1 participants	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-450 in Non-structural Viral Protein 3 (NS3) Day 4: Resistance to ABT-450 >10-fold (n=3, 2, 3)	1 participants	1 participants	0 participants	—	—	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and Day 4

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the analysis. When the number of participants used to analyze the data at a specific time point differs from the Number of Participants Analyzed, the n (number of participants) is denoted in the Category Title.

Baseline samples were analyzed for resistance-associated amino acid variants using population and clonal sequencing and were compared with the appropriate reference sequence (1a-H77 or 1b-Con1). Phenotypic resistance to ABT-072 at baseline was assessed by calculating the fold difference in the half maximal effective concentration (EC50) compared with the EC50 for the appropriate reference replicon (1a-H77 or 1b-Con1). Available samples at Day 4 with HCV RNA ≥ 1000 IU/mL were analyzed for the presence of resistance-associated variants using population and clonal sequencing and were compared with the baseline sequences to assess amino acid changes. Phenotypic resistance to ABT-072 at Day 4 was assessed by calculating the fold difference in the EC50 compared with the EC50 for the corresponding baseline sample. The number of participants with variants at resistance-associated amino acid positions and phenotypic resistance are presented.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=7 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-072 in Non-structural Viral Protein 5B (NS5B) Baseline Variants in NS5B	0 participants	1 participants	0 participants	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-072 in Non-structural Viral Protein 5B (NS5B) Baseline Resistance to ABT-072 >10-fold	0 participants	1 participants	0 participants	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-072 in Non-structural Viral Protein 5B (NS5B) Day 4: Variants in NS5B (n=6, 7, 6)	1 participants	2 participants	1 participants	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-072 in Non-structural Viral Protein 5B (NS5B) Day 4: Resistance to ABT-072 >10-fold (n=6, 7, 6)	0 participants	0 participants	1 participants	—	—	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and Day 4

Population: All participants who received at least one dose of study drug (direct-acting antiviral agent) were included in the analysis. When the number of participants used to analyze the data at a specific time point differs from the Number of Participants Analyzed, the n (number of participants) is denoted in the Category Title.

Baseline samples were analyzed for resistance-associated amino acid variants using population and clonal sequencing and were compared with the appropriate reference sequence (1a-H77 or 1b-Con1). Phenotypic resistance to ABT-333 at baseline was assessed by calculating the fold difference in the half maximal effective concentration (EC50) compared with the EC50 for the appropriate reference replicon (1a-H77 or 1b-Con1). Available samples at Day 4 with HCV RNA ≥ 1000 IU/mL were analyzed for the presence of resistance-associated variants using population and clonal sequencing and were compared with the baseline sequences to assess amino acid changes. Phenotypic resistance to ABT-333 at Day 4 was assessed by calculating the fold difference in the EC50 compared with the EC50 for the corresponding baseline sample. The number of participants with variants at resistance-associated amino acid positions and phenotypic resistance are presented.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=8 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-333 in Non-structural Viral Protein 5B (NS5B) Baseline Variants in NS5B	1 participants	2 participants	—	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-333 in Non-structural Viral Protein 5B (NS5B) Baseline Resistance to ABT-333 >10-fold NS5B	0 participants	1 participants	—	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-333 in Non-structural Viral Protein 5B (NS5B) Day 4: Variants in NS5B (n=7, 8)	3 participants	3 participants	—	—	—	—	—	—	—
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-333 in Non-structural Viral Protein 5B (NS5B) Day 4: Resistance to ABT-333 >10-fold (n=7, 8)	0 participants	0 participants	—	—	—	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline up to Post-treatment Week 24

Population: Participants received at least one dose of study drug (direct-acting antiviral agent) and have both baseline and at least one post-baseline measurement of HCV RNA levels during monotherapy treatment.

The Hepatitis C Virus Patient-report Outcomes (HCV-PRO, formerly known as HCV Quality of Life) survey was used to assess disease-specific function and well-being on a scale from 0 to 100; a higher score indicated relatively good function and well-being of treated participants. Data presented are the summaries across all participants, for each treatment arm, regardless of dose. Data are reported as the group mean change from baseline ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=12 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=13 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=10 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=4 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Change From Baseline in Hepatitis C Virus Patient-reported Outcomes (HCV-PRO) Total Score	-0.78 units on a scale Standard Deviation 15.53	-0.37 units on a scale Standard Deviation 13.97	-3.25 units on a scale Standard Deviation 14.72	-9.04 units on a scale Standard Deviation 12.41	—	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and Post-treatment Week 24

Population: Participants received at least one dose of study drug (direct-acting antiviral agent) and have both baseline and at least one post-baseline measurement of HCV RNA levels during monotherapy treatment.

The ED-5D VAS was a self-rating survey used to capture the current health status of a participant and ranged from 0 (the worst imaginable health state) to 100 (best imaginable health state). Data presented are the summaries across all participants, for each treatment arm, regardless of dose. Data are presented as the group mean change from baseline ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=11 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=13 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=11 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=4 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Change From Baseline in ED-5D Visual Analog Scale (ED-5D VAS) Score	-5.91 units on a scale Standard Deviation 31.92	-2.38 units on a scale Standard Deviation 29.86	11.18 units on a scale Standard Deviation 27.19	-9.00 units on a scale Standard Deviation 22.23	—	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and Post-treatment Week 24

Population: Participants received at least one dose of study drug (direct-acting antiviral agent) and have both baseline and at least one post-baseline measurement of HCV RNA levels during monotherapy treatment.

The EQ-5D was a health state questionnaire used to measure five health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The combination of responses from all five dimensions were derived into an index score ranging from 0 to 1; a higher score indicated a more preferable health utility value from the societal perspectives. Data presented are the summaries across all participants, for each treatment arm, regardless of dose. Data are presented as the group mean change from baseline ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=12 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=13 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=11 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=4 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Change From Baseline in EQ-5D (3 Level) Health Index Score	-0.06 units on a scale Standard Deviation 0.22	-0.06 units on a scale Standard Deviation 0.15	-0.02 units on a scale Standard Deviation 0.17	-0.09 units on a scale Standard Deviation 0.09	—	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and Post-treatment Week 24

Population: Participants received at least one dose of study drug (direct-acting antiviral agent) and have both baseline and at least one post-baseline measurement of HCV RNA levels during monotherapy treatment.

The Physical Component Summary (PCS) of the SF-36 was used to measure the overall physical health status of a participant. The aggregated score of the SF-36 PCS score was standardized using a linear T-score transformation with a mean of 50 and a standard deviation of 10; a higher score indicated better physical function and well-being. Data presented are the summaries across all participants, for each treatment arm, regardless of dose. Data are presented as the group mean change from baseline ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=11 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=13 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=11 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=4 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Change From Baseline in SF-36 Physical Component Summary (PCS)	3.01 units on a scale Standard Deviation 6.15	-1.92 units on a scale Standard Deviation 5.89	4.08 units on a scale Standard Deviation 5.76	-2.84 units on a scale Standard Deviation 7.92	—	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and Post-treatment Week 24

Population: Participants received at least one dose of study drug (direct-acting antiviral agent) and have both baseline and at least one post-baseline measurement of HCV RNA levels during monotherapy treatment.

The Mental Component Summary (MCS) of the SF-36 was used to measure the overall mental health status of participants. The aggregated score of the SF-36 MPS was standardized using a linear T-score transformation with a mean of 50 and a standard deviation of 10; a higher score indicated better mental function and well-being. Data presented are the summaries across all participants, for each treatment arm, regardless of dose. Data are presented as the group mean change from baseline ± standard deviation.

Outcome measures

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + pegIFN/RBV n=11 Participants Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + pegIFN/RBV n=13 Participants Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + pegIFN/RBV n=11 Participants Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + pegIFN/RBV n=4 Participants Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + pegIFN/RBV Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + pegIFN/RBV Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + pegIFN/RBV Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + pegIFN/RBV Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + pegIFN/RBV Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Change From Baseline in SF-36 Mental Component Summary (MCS)	-2.77 units on a scale Standard Deviation 5.99	-0.41 units on a scale Standard Deviation 10.64	-4.37 units on a scale Standard Deviation 11.00	-10.29 units on a scale Standard Deviation 11.35	—	—	—	—	—

Adverse Events

ABT-450/r (50/100 mg) Once Daily (QD) + (pegIFN/RBV)

Serious events: 1 serious events

Other events: 8 other events

Deaths: 0 deaths

ABT-450/r (100/100 mg) Once Daily (QD) + (pegIFN/RBV)

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

ABT-450/r (200/100 mg) Once Daily (QD) + (pegIFN/RBV)

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

ABT-072 (100 mg) Once Daily (QD) + (pegIFN/RBV)

Serious events: 1 serious events

Other events: 8 other events

Deaths: 0 deaths

ABT-072 (300 mg) Once Daily (QD) + (pegIFN/RBV)

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

ABT-072 (600 mg) Once Daily (QD) + (pegIFN/RBV

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

ABT-333 (400 mg) Twice a Day (BID) + (pegIFN/RBV)

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

ABT-333 (800 mg) Twice Daily (BID) + (pegIFN/RBV)

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Placebo + (pegIFN/RBV)

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Serious adverse events

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + (pegIFN/RBV n=7 participants at risk Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + (pegIFN/RBV) n=8 participants at risk Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + (pegIFN/RBV) n=8 participants at risk Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + (pegIFN/RBV) n=11 participants at risk Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Gastrointestinal disorders HAEMORRHOIDS	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MALIGNANT MELANOMA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).

Other adverse events

Measure	ABT-450/r (50/100 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (100/100 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-450/r (200/100 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (100 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (300 mg) Once Daily (QD) + (pegIFN/RBV) n=8 participants at risk Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-072 (600 mg) Once Daily (QD) + (pegIFN/RBV n=7 participants at risk Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (400 mg) Twice a Day (BID) + (pegIFN/RBV) n=8 participants at risk Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	ABT-333 (800 mg) Twice Daily (BID) + (pegIFN/RBV) n=8 participants at risk Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.	Placebo + (pegIFN/RBV) n=11 participants at risk Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
Infections and infestations TOOTH ABSCESS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations TOOTH INFECTION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations HERPES SIMPLEX	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations INFLUENZA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations LOCALISED INFECTION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations SINUSITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations SKIN INFECTION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations NASOPHARYNGITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations ORAL CANDIDIASIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations PERITONSILLAR ABSCESS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations PHARYNGITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Blood and lymphatic system disorders ANAEMIA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Blood and lymphatic system disorders LEUKOPENIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Blood and lymphatic system disorders LYMPHADENOPATHY	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Blood and lymphatic system disorders NEUTROPENIA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	62.5% 5/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Blood and lymphatic system disorders THROMBOCYTOPENIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Ear and labyrinth disorders CERUMEN IMPACTION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Ear and labyrinth disorders TINNITUS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Eye disorders CONJUNCTIVITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Eye disorders LACRIMATION INCREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Eye disorders MACULAR OEDEMA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Eye disorders RETINAL DETACHMENT	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Eye disorders RETINAL EXUDATES	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Eye disorders VISION BLURRED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Eye disorders VISUAL ACUITY REDUCED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders ABDOMINAL DISCOMFORT	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders ABDOMINAL DISTENSION	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders ABDOMINAL PAIN	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders ABDOMINAL PAIN UPPER	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders APHTHOUS STOMATITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders CONSTIPATION	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	42.9% 3/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders DIARRHOEA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	28.6% 2/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	36.4% 4/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders DRY MOUTH	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders DYSPEPSIA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders FLATULENCE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders GASTROOESOPHAGEAL REFLUX DISEASE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders GINGIVITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders GLOSSODYNIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders HAEMORRHOIDS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders LIP DRY	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders LOOSE TOOTH	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders MOUTH ULCERATION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders NAUSEA	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	28.6% 2/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	36.4% 4/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders PROCTALGIA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders PROCTITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders RECTAL HAEMORRHAGE	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders STOMATITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Gastrointestinal disorders VOMITING	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	28.6% 2/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders APPLICATION SITE RASH	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders ASTHENIA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders CHILLS	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders FATIGUE	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	50.0% 4/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	75.0% 6/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	42.9% 3/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	50.0% 4/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	54.5% 6/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders INFLUENZA LIKE ILLNESS	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	50.0% 4/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders INFUSION SITE INFLAMMATION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders INJECTION SITE ERYTHEMA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders INJECTION SITE HAEMATOMA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders INJECTION SITE RASH	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders INJECTION SITE REACTION	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders IRRITABILITY	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders MALAISE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders NON-CARDIAC CHEST PAIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders PAIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders PYREXIA	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders TEMPERATURE INTOLERANCE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
General disorders THIRST	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Hepatobiliary disorders HEPATOMEGALY	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations ANAL ABSCESS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations CANDIDIASIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations CELLULITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations EAR INFECTION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations GASTROENTERITIS	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Injury, poisoning and procedural complications BURNS THIRD DEGREE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Injury, poisoning and procedural complications EXCORIATION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Injury, poisoning and procedural complications THERMAL BURN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations BLOOD BILIRUBIN INCREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations BLOOD CREATININE INCREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations BLOOD GLUCOSE INCREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations BLOOD PHOSPHORUS DECREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations BLOOD POTASSIUM DECREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations BLOOD TRIGLYCERIDES INCREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations CREATININE RENAL CLEARANCE DECREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations GAMMA-GLUTAMYLTRANSFERASE INCREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations HAEMOGLOBIN DECREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations LYMPHOCYTE COUNT DECREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations NEUTROPHIL COUNT DECREASED	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations PLATELET COUNT DECREASED	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations WEIGHT DECREASED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Investigations WHITE BLOOD CELL COUNT DECREASED	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Metabolism and nutrition disorders DECREASED APPETITE	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	28.6% 2/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Metabolism and nutrition disorders DEHYDRATION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Metabolism and nutrition disorders HYPOPHOSPHATAEMIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Metabolism and nutrition disorders INCREASED APPETITE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders ARTHRALGIA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	42.9% 3/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders AXILLARY MASS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders BACK PAIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	36.4% 4/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders COSTOCHONDRITIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders FLANK PAIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders JOINT STIFFNESS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders MUSCLE SPASMS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders MUSCLE TIGHTNESS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL CHEST PAIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL PAIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders MYALGIA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	42.9% 3/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	27.3% 3/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders NECK PAIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders DISTURBANCE IN ATTENTION	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders DIZZINESS	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	42.9% 3/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	36.4% 4/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders DYSGEUSIA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	42.9% 3/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders HEADACHE	75.0% 6/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	50.0% 4/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	62.5% 5/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	87.5% 7/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	62.5% 5/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	71.4% 5/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	50.0% 4/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	36.4% 4/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders HYPOAESTHESIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders MEMORY IMPAIRMENT	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders RESTLESS LEGS SYNDROME	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders SINUS HEADACHE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Nervous system disorders SOMNOLENCE	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders ABNORMAL DREAMS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders AFFECT LABILITY	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders AGITATION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders ANGER	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders ANXIETY	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders CONFUSIONAL STATE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders DEPRESSED MOOD	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders DEPRESSION	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	50.0% 4/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders IMPATIENCE	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders INSOMNIA	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	62.5% 5/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders MOOD SWINGS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Psychiatric disorders RESTLESSNESS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Renal and urinary disorders DYSURIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Renal and urinary disorders POLLAKIURIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Renal and urinary disorders URINE ODOUR ABNORMAL	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Reproductive system and breast disorders VULVOVAGINAL PRURITUS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders COUGH	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders DYSPHONIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders DYSPNOEA	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders DYSPNOEA EXERTIONAL	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders EPISTAXIS	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders OROPHARYNGEAL PAIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders PRODUCTIVE COUGH	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders RHINORRHOEA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders SINUS CONGESTION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Respiratory, thoracic and mediastinal disorders UPPER-AIRWAY COUGH SYNDROME	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders ALOPECIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders DERMATITIS	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders DRY SKIN	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders ERYTHEMA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders HYPERHIDROSIS	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders PRURITUS	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders PRURITUS GENERALISED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders RASH	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	37.5% 3/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	25.0% 2/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	18.2% 2/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders RASH GENERALISED	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	28.6% 2/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders RASH MACULO-PAPULAR	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders RASH PAPULAR	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders SKIN LESION	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Skin and subcutaneous tissue disorders URTICARIA	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Vascular disorders HOT FLUSH	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	14.3% 1/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	9.1% 1/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).
Vascular disorders HYPERTENSION	12.5% 1/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/7 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/8 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).	0.00% 0/11 • Adverse events were collected from the time of study drug administration to 30 days after last dose of ABT-450/r, ABT-267, or ABT-333 (16 Weeks); Serious adverse events were also collected from the time that informed consent was obtained (76 weeks ).

Additional Information

Global Medical Information

AbbVie (prior sponsor, Abbott)

Phone: 800-633-9110

Results disclosure agreements

• Principal investigator is a sponsor employee AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
• Publication restrictions are in place

Restriction type: OTHER